ClinicalTrials.gg
CompletedNCT03930446(DARC)Updated Apr 25, 2022Results posted

Alcohol, Behavior, and Brain Imaging

An Early Phase 1 interventional study of Ethanol and Placebo in Alcohol Drinking, Binge Drinking and Drinking Behavior, sponsored by University of Chicago. Completed. Open to participants aged 21 Years to 29 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-25.

Primary conditionBinge DrinkingRegistry: Alcohol DrinkingReclassifiedWhy we changed it
Registry
Alcohol Drinking — the first condition term the registry derived for this study.
ClinicalTrials.gg
Binge Drinking
Why
  1. Alcohol Drinking is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Binge Drinking, a narrower term within Alcohol Drinking.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Chicago · Early Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 3 years 3 months after the study started (first participant enrolled Jan 2016, registered Apr 2019).
Phase
Early Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
21 Years to 29 Years
Sex
All
01

Study summary

To evaluate the relationship of extraversion to both the acute subjective and behavioral effects of alcohol, and the neural reactivity to the anticipation of reward.

02

Conditions studied

  • Alcohol Drinking
  • Binge Drinking
  • Drinking Behavior
  • Substance-Related Disorders
  • Ethanol
  • Physiological Effects of Drugs
  • Central Nervous System Depressants

Browse trials for

03

In context

Binge Drinking Reclassified

71 studies on the registry are indexed under Binge Drinking; 20 are open to participants now.

This study's enrollment of 80 is below the median of 120 across 64 interventional studies indexed under Binge Drinking.

Browse Binge Drinking studies →

Lead sponsor

University of Chicago is the lead sponsor of 924 studies on the registry; 185 are open to participants now.

Of its 103 completed or terminated interventional studies of FDA-regulated products, 72 (70%) have results posted.

Compared within Binge Drinking, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Alcohol Drinking. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
21 Years to 29 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • 21-29 years old
  • 7-30 alcoholic drinks per week (as reported on PHQ or TLFB)
  • At least one binge episode (4 for females/5 for males) per month
  • No 'flushing' reaction to alcohol
  • Females must be on or in the beginning of follicular phase (1-14 days after start of menstruation)
  • 19-26
  • High school education or greater, fluent in English
  • No night shift work
  • No current or past year Axis I psychiatric disorder including drug/alcohol dependence
  • No current psychopharmacological treatment
  • No lifetime ADHD or prescription for ADHD medication
  • No abnormal , cardiovascular illness, high blood pressure
  • No medical condition or pharmacological treatment for which alcohol is
  • Not pregnant, lactating, or planning to become pregnant
  • Smoke \<6 cigarettes per day
  • No previous participation in studies that have used the Stop Task (except IDAC) o Previous Stop Task studies: GOI, CAP, STEM, JAM, MACI, PAC, CAM
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Ethanol

    Subjects will receive 4 color-coded beverages in green or blue cups, containing ethanol (0.2 g/kg per dose, total dose 0.8 g/kg).

    Drug: Ethanol

  • Placebo comparator
    Placebo (Juice)

    Subjects will receive 4 color-coded beverages in green or blue cups, containing placebo (Juice).

    Other: Placebo

Interventions

  • The 0.8 g/kg body weight dose of oral alcohol (190-proof ethanol) will be divided into 4 servings of 0.2 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol. Women will receive a reduced dose (0.68 g/kg) to account for sex differences in total body water

  • OtherPlacebo

    The placebo beverage will consist of the cranberry or orange juice plus 1% alcohol added as a taste mask. All beverages will be sprayed with an alcoholic mist to provide a strong alcoholic scent.

06

What researchers measure

Primary outcomes

  1. Stop Signal Task (SST)

    The Stop-Signal Task (SST) is a task requiring inhibition of a prepotent motor response. The SST requires participants to respond to a target stimulus as quickly and accurately as possible by pressing a button, but also to withhold their response when they hear an auditory signal. Thus, this task involves a competition between activating and inhibiting processes. The primary outcome variable is change in the stop signal reaction time (SSRT) for the task administered seconds to minutes before and seconds to minutes after stimulation. The theoretical minimum is zero seconds and there is no theoretical maximum. Higher SSRT scores reflect greater impulsivity.

    Time frame: Within an hour post-stimulation condition

07

Results

Posted Apr 25, 2022

Participant flow

Participant flow — Overall Study
MilestoneEthanolPlacebo (Juice)
Started4040
Completed4040
Not completed00

Outcome measures

PrimaryStop Signal Task (SST)

The Stop-Signal Task (SST) is a task requiring inhibition of a prepotent motor response. The SST requires participants to respond to a target stimulus as quickly and accurately as possible by pressing a button, but also to withhold their response when they hear an auditory signal. Thus, this task involves a competition between activating and inhibiting processes. The primary outcome variable is change in the stop signal reaction time (SSRT) for the task administered seconds to minutes before and seconds to minutes after stimulation. The theoretical minimum is zero seconds and there is no theoretical maximum. Higher SSRT scores reflect greater impulsivity.

Time frame:
Within an hour post-stimulation condition
Reported as:
Mean · milliseconds
Stop Signal Task (SST)
millisecondsEthanolPlacebo (Juice)
Stop Signal Task (SST)255 ± 463215 ± 278

Adverse events

Collected over Through study completion, an average of 5 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ethanol0/40 (0%)0/40 (0%)0/40 (0%)
Placebo (Juice)0/40 (0%)0/40 (0%)0/40 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)EthanolPlacebo (Juice)Total
<=18 years000
Between 18 and 65 years404080
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)EthanolPlacebo (Juice)Total
Female202040
Male202040
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EthanolPlacebo (Juice)Total
American Indian or Alaska Native000
Asian336
Native Hawaiian or Other Pacific Islander000
Black or African American5510
White222244
More than one race9918
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(participants)EthanolPlacebo (Juice)Total
United States404080
Education - High School Education
Education - High School Education(Participants)EthanolPlacebo (Juice)Total
Count of participants404080
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Li J, Murray CH, Weafer J, de Wit H. Subjective Effects of Alcohol Predict Alcohol Choice in Social Drinkers. Alcohol Clin Exp Res. 2020 Dec;44(12):2579-2587. doi: 10.1111/acer.14476. Epub 2020 Nov 17. PubMed 33201577 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03930446
Responsible party
Sponsor
First posted
Apr 29, 2019
Start date
Jan 1, 2016
Primary completion
May 30, 2019
Completion
May 30, 2019
Results posted
Apr 25, 2022
Last update
Apr 25, 2022

Study contacts

Jessica Weafer
principal investigator · University of Chicago

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ethanol

Start the discussion